Want to see HCAT full AI Analyst Report?
HCAT Stock Chart & Stats
$1.32
$0.34(4.94%)
At close: 4:00 PM EST
$1.32
$0.34(4.94%)
Day’s Range― - ―
52-Week Range$0.96 - $4.12
Previous CloseN/A
Volume315.36K
Average Volume (3M)628.93K
Market Cap
$168.48M
Enterprise Value$153.95
Total Cash (Recent Filing)$108.82M
Total Debt (Recent Filing)$170.58M
Price to Earnings (P/E)―
Beta1.44
Next Earnings
Aug 12, 2026EPS Estimate
0.03Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.72
Shares Outstanding73,894,020
10 Day Avg. Volume592,331
30 Day Avg. Volume628,929
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)0.68
Price to Sales (P/S)0.54
P/FCF Ratio-704.86
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$2.08Price Target Upside57.83% Upside
Rating ConsensusHold
Number of Analyst Covering8
EPS Forecast (FY)0.04
Revenue Forecast (FY)$263.12M
Bulls Say, Bears Say
Bulls Say
Balance Sheet De‑riskingMaterial deleveraging meaningfully reduces refinancing and covenant risk, freeing cash flow for operations and strategic initiatives. Lower leverage increases financial flexibility over multiple quarters, enabling management to fund AI/product investments or absorb transition costs without immediate external funding.
Positive Cash GenerationReturn to positive operating and free cash flow signals improving cash conversion and operational discipline. Sustainable cash generation supports ongoing product development, restructuring costs, and any debt paydown, providing a durable liquidity cushion during multi-quarter execution of Project NEXUS.
Strategic Portfolio SimplificationDivesting non-core Vitalware monetizes an asset to eliminate the term loan and concentrate resources on higher‑conviction AI analytics. This structural move tightens strategic focus, reduces management complexity, and reallocates capital to the core cloud analytics business across the medium term.
Bears Say
Weak Revenue TrendStagnant and slightly negative top-line growth constrains operating leverage and limits the company's ability to scale gross‑margin gains into sustainable profitability. Over several quarters weak revenue growth increases dependence on cost cuts or divestitures to hit profit targets.
Structural UnprofitabilityDeep and persistent net losses erode equity value and limit reinvestment capacity. Even with improving gross margins and positive cash flow, the magnitude of operating losses requires consistent execution on cost reductions and revenue retention to achieve sustainable profitability over multiple quarters.
Migration Churn And At‑risk ARRLarge customer migration and downsell exposure weakens the recurring revenue base and increases execution risk. Losses or delays from migration-related churn can compress near-term revenue and margins, complicating the path to sustained growth and making multi-quarter forecasts more uncertain.
Health Catalyst News
HCAT FAQ
What was Health Catalyst’s price range in the past 12 months?
Health Catalyst lowest stock price was $0.95 and its highest was $4.12 in the past 12 months.
What is Health Catalyst’s market cap?
Health Catalyst’s market cap is $168.48M.
When is Health Catalyst’s upcoming earnings report date?
Health Catalyst’s upcoming earnings report date is Aug 12, 2026 which is in 26 days.
How were Health Catalyst’s earnings last quarter?
Health Catalyst released its earnings results on May 11, 2026. The company reported $0.02 earnings per share for the quarter, beating the consensus estimate of $0.011 by $0.009.
Is Health Catalyst overvalued?
According to Wall Street analysts Health Catalyst’s price is currently Undervalued.
Does Health Catalyst pay dividends?
Health Catalyst does not currently pay dividends.
What is Health Catalyst’s EPS estimate?
Health Catalyst’s EPS estimate is 0.03.
How many shares outstanding does Health Catalyst have?
Health Catalyst has 73,894,020 shares outstanding.
What happened to Health Catalyst’s price movement after its last earnings report?
Health Catalyst reported an EPS of $0.02 in its last earnings report, beating expectations of $0.011. Following the earnings report the stock price went up 7.246%.
Which hedge fund is a major shareholder of Health Catalyst?
Currently, no hedge funds are holding shares in HCAT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Health Catalyst Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$2.08 (57.83% Upside)
$2.08 (57.83% Upside)
Blogger Sentiment
Bullish
HCAT Sentiment 100%
Sector Average 66%
Sector Average 66%
Hedge Fund Trend
Decreased
By 793.7K Shares
Last Quarter.
Last Quarter.
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-65.50%
12-Months-Change
Fundamentals
Return on Equity
-99.78%
Trailing 12-Months
Asset Growth
-53.77%
Trailing 12-Months
Company Description
Health Catalyst
Health Catalyst, Inc. equips healthcare providers with crucial data and analytical technologies, alongside specialized services. Their extensive product line features a robust, enterprise-level data and analytics platform designed specifically for the healthcare sector. They additionally offer advanced artificial intelligence (AI) and data science solutions that integrate AI seamlessly into existing business intelligence tools, thereby enhancing analytical precision. The company's services also cover population health management, which identifies areas for improvement throughout the patient care journey, offering actionable recommendations and automated processes. For financial effectiveness, they provide critical insights into cost analysis, workforce efficiency, and revenue maximization. Moreover, Health Catalyst contributes to improving quality and safety by leveraging clinical and patient safety data, sophisticated analytics, and expert consulting. They also facilitate a national data ecosystem, promoting collaborative thought leadership and shared knowledge to generate groundbreaking insights that redefine healthcare delivery. Established in 2008 and based in South Jordan, Utah, the company was formerly known as HQC Holdings, Inc. before officially becoming Health Catalyst, Inc. in March 2017.
HCAT Stock 12 Month Forecast
Average Price Target
$2.08
▲(57.83% Upside)
Technical Analysis
HealthStream
―
OptimizeRx
―
Evolent Health
―
SOPHiA GENETICS
―
Definitive Healthcare Corp
―
Ownership Overview
7.36% Insiders
13.29% Mutual Funds
0.19% Other Institutional Investors
72.82% Public Companies and
Individual Investors